MERRIE CHERRY: Open Payments
NPI 1336287762 · LEXINGTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$26,873 in 240 payments from 17 companies in 2025. Trend: 2023 $3,409 · 2024 $3,687 · 2025 $26,873
Speaker / faculty: $13,000Consulting: $6,800Food & beverage: $4,457Travel & lodging: $2,616
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 52 | $23,432 |
| ABBVIE INC. | 43 | $577 |
| E.R. Squibb & Sons, L.L.C. | 21 | $517 |
| Otsuka America Pharmaceutical, Inc. | 18 | $507 |
| Teva Pharmaceuticals USA, Inc. | 34 | $463 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $343 |
| Vanda Pharmaceuticals Inc. | 12 | $194 |
| Alkermes, Inc. | 10 | $168 |
| Janssen Pharmaceuticals, Inc | 9 | $157 |
| Tris Pharma Inc | 6 | $110 |
Products named: INGREZZA, COBENFY, VRAYLAR, REXULTI, CAPLYTA, UZEDY, AUSTEDO XR, ARISTADA.
Industry payments across SC — which companies pay providers there.
